Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.34 |
| ▸ | FAAH | O00519 | 5/20 | 0.33 |
| ▸ | DRD2 | P14416 | 5/20 | 0.33 |
| ▸ | DRD3 | P35462 | 5/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414065 | 0.95 | PDE2A (0.56) | PDE2APDE4DTP53MAPTFYN | |
| SCHEMBL4412620 | 0.94 | PDE2A (0.60) | PDE2APDE4DTP53MAPTFYN | |
| SCHEMBL4602359 | 0.91 | PDE2A (0.58) | PDE2APDE4DTP53MAPTFYN | |
| SCHEMBL4424399 | 0.87 | PDE2A (0.60) | PDE2APDE4DTP53MAPTFYN | |
| SCHEMBL4414019 | 0.84 | PDE2A (0.57) | PDE2APDE4DTP53MAPTPTGDR2 | |
| SCHEMBL4411561 | 0.84 | PDE2A (0.58) | PDE2ATP53MAPTFYNPTGDR2 | |
| SCHEMBL4412658 | 0.83 | PDE2A (0.72) | PDE2APDE4DFYNFAAHDRD2 | |
| SCHEMBL4410766 | 0.81 | GABRA1 (0.42) | PDE2APDE4DTP53MAPTPTGDR2 | |
| SCHEMBL4707980 | 0.80 | PDE2A (0.67) | PDE2APDE4DTP53MAPTFYN | |
| SCHEMBL4410915 | 0.79 | GABRA1 (0.46) | PDE2APDE4DTP53MAPTPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2009-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | PDE12, PDE4B, PDE2A | PDE2A 3/4885PDE4D 13/4885TP53 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.